
Santhera Pharmaceuticals Holding Ag (($CH:SANN)) has held its Q2 earnings call. Read on for the main highlights of the call. Santhera Pharmaceuticals’ latest earnings call struck a distinctly upbeat tone,
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| SPHDF | Santhera Pharmaceuticals Holding | 18.30 | 5.05 | 38.11% |
| Name | Price | % Change | |
|---|---|---|---|
| $18.30 | +38.11% |

Santhera Pharmaceuticals Holding Ag (($CH:SANN)) has held its Q2 earnings call. Read on for the main highlights of the call. Santhera Pharmaceuticals’ latest earnings call struck a distinctly upbeat tone,

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Santhera Pharmaceuticals Holding today and set a price target of CHF30.00. Ram Selvaraju has given his Buy rating due to

Santhera Pharmaceuticals Holding, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on the stock and has

Ram Selvaraju, an analyst from H.C. Wainwright, reiterated the Buy rating on Santhera Pharmaceuticals Holding. The associated price target remains the same with CHF30.00. Ram Selvaraju has given his Buy

Santhera Pharmaceuticals Holding Ag (($SPHDF)) announced an update on their ongoing clinical study. Santhera Pharmaceuticals is conducting a study titled ‘An Open-label Study to Collect Safety and Effectiveness Information on

Santhera Pharmaceuticals Holding Ag (($CH:SANN)) has held its Q2 earnings call. Read on for the main highlights of the call. Santhera Pharmaceuticals Holding AG’s recent earnings call conveyed a generally

Santhera Pharmaceuticals Holding Ag ( ($SPHDF) ) has released its Q2 earnings. Here is a breakdown of the information Santhera Pharmaceuticals Holding Ag presented to its investors. Santhera Pharmaceuticals Holding

H.C. Wainwright raised the firm’s price target on Santhera Pharmaceuticals (SPHDF) to CHF 30 from CHF 25 and keeps a Buy rating on the shares. Santhera remains engaged in various

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Santhera Pharmaceuticals Holding (SPHDF – Research Report) today and set a price target of CHF30.00. Ram Selvaraju has given his

Santhera Pharmaceuticals Holding Ag ( ($SPHDF) ) has released its Q4 earnings. Here is a breakdown of the information Santhera Pharmaceuticals Holding Ag presented to its investors. Santhera Pharmaceuticals Holding
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| buy | Reiterated | Jul 2, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Apr 29, 2027TBA | $231.93M | ― | $44.42M | -1.37 | -5.58 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.